Q2 2023 QuidelOrtho Corp Earnings Call
But those of you participating on the conference call there will be an opportunity for your questions at the end of today's prepared remarks.
Please note this conference call is being recorded.
And audio replay of the conference call will be available on the company's website. Shortly after this call.
I would now like to turn the call over to Brian Brookmyre, Vice President of Investor Relations Brian .
Thank you operator, good afternoon, everyone and welcome to the quite all Ortho second quarter financial results Conference call with me today to discuss our financial results are Doug Bryant, but all ortho as president and CEO and Joe Buskey, but all ortho Chief Financial Officer.
The conference call is being simultaneously webcast to the Investor Relations page of our website and a version of today's presentation can be downloaded there.
Before we begin I will cover our safe Harbor statement.
Statements, we will make during this call about the company's expectations plans and future performance and prospects.
Our forward looking statements within the meaning of the private Securities Litigation Reform Act of 1995, which provides a safe harbor for such statements.
Forward looking statements are subject to a number of risks uncertainties and other factors that could cause actual results to differ materially from those expressed or implied in these forward looking statements.
These risks and uncertainties include but are not limited to those factors identified in the risk factors in our annual report on Form 10-K filed with the SEC on February 20, <unk> 2003.
Thanks, Doug.
With the SEC.
Please refer to our SEC filings for a more detailed discussion of forward looking statements.
The risks and uncertainties of such statements.
We cannot assure you that the forward looking statements, we make or implied by our statements will be realized. Furthermore, such forward looking statements represent management's judgment and expectations as of today.
Welcome to Quad they'll ortho second quarter 2023 financial results conference call and webcast.
At this time all participant lines are in a listen only mode.
Except as required by law, we undertake no obligation to update any forward looking statements or any time sensitive information to reflect future events developments or changed circumstances or for any other reason.
For those of you participating on the conference call there will be an opportunity for your questions at the end of today's prepared remarks.
Please note this conference call is being recorded.
Also during today's call to facilitate the comparison of the Companys operating performance from the second quarter of 2022 before the quite outward combination the second quarter of 2023.
And audio replay of the conference call will be available on the company's website. Shortly after this call.
I would now like to turn the call over to Brian Meyer, Vice President of Investor Relations Brian .
We will be discussing supplemental revenue into other supplemental adjusted operating result, quite old and ortho had been combined for the applicable periods.
Thank you operator, good afternoon, everyone and welcome to the bright outlook second quarter financial results Conference call with me today to discuss our financial results are Brian <unk>, President and CEO , and Joe Buskey Chief Financial Officer.
We will refer to the information in our supplemental combined information.
In the supplemental combined information as well as certain other items, we will got us.
Warranty use to how they accepted accounting principles or.
Conference call is being simultaneously webcast to the Investor Relations page of our website and a version of today's presentation can be downloaded there.
Please see slide three for our list of non-GAAP measures reconciliations of these non-GAAP measures to their most directly comparable GAAP measures are included in the appendix to the Investor presentation and press release issued this afternoon, both of which are available on our Investor Relations page of the quite unaware of the website.
Before we begin I will cover our safe Harbor statements.
Statements, we will make during this call about the company's expectations plans future performance and prospects are forward looking statements within the meaning of the private Securities Litigation Reform Act of 995.
Unless stated otherwise all year over year revenue growth rates, including revenue growth ranges given on today's call are given on a constant currency.
The safe Harbor for such statements.
Forward looking statements are subject to a number of risks uncertainties and other factors that could cause actual results to differ materially from those expressed or implied in these forward looking statements.
Comparable constant currency basis, now I'd like to turn the call over to Brian .
No.
Thanks, Brian and welcome everybody and thanks for joining our call.
We're just march and incredibly exciting first year of harmonization.
And integration across the global <unk> organization.
Our colleagues have performed admirably.
And we as United team has successfully achieved major milestones.
In a very short timeframe.
We delivered solid financial results in the second quarter with revenue of $665 million and non respiratory revenue was up 4% on a supplemental combined basis demand for diagnostics across the healthcare continuum remained strong and our labs business delivered.
A single digit growth.
Our team was steadfast in executing our key growth drivers this quarter.
Labs business backlog approach, a normalized levels and we saw utilization increase.
So fee of non COVID-19 pull through continued to increase and.
And we completed both the Savannah, EUA and slide 10-K, FDA submissions as planned including 5% in case of the instrument and both RVP.
Mmk that information.
Find information <unk>.
Michael combine information as well as getting other items. So we will not conform to us to hardly accepted accounting <unk>. Please.
In Hs the lesion panels.
Five three for a list of non-GAAP measures Arkansas.
Drilling down into the results from our four business units first our labs business delivered 9% growth in non security revenue with.
Reconciliation for these non-GAAP measures to their most directly comparable GAAP measures are included in the appendix to the Investor presentations and press release issued this afternoon.
With growth across all major geographic regions with notable global strength and clinical chemistry was driven by expected utilization levels per instrument and a strong integrated instrument placements over the last few years.
Both of which are available on our on the Investor Relations page of the quiet all of the website.
Lastly, unless stated otherwise all year over year revenue growth rates, including revenue growth ranges given on today's call are given on a constant currency.
Each also drove solid growth in immunoassay and it's clearly helpful to gross margin.
On a comparable constant currency basis, now I'd like to turn the call over to stop by.
Instrument demand remained healthy across all regions.
President.
Hello.
Thanks, Brian welcome everybody and thanks for joining our call.
Focused execution by our operations team enabled us to produce nearly 10% more instruments.
We're just march and incredibly exciting first year of harmonization.
Our record breaking first quarter and reduced our instrument backlog in our labs business by approximately 40%.
And integration across the global quite a bill or organization.
Our colleagues have performed admirably.
These efforts enabled us to ship more instruments than previously anticipated in the quarter as a result, our integrated installed base grew 13%.
And we as a United team has successfully achieved major milestones.
In a very short time frame.
We delivered solid financial results in the second quarter with revenue of $665 million.
And automation increased 20% continuing the positive trend that we've seen since implementing our commercial excellence program and launching our features X dollars 7600 integrated system in late 2018.
And non respiratory revenue was at 4% on a supplemental combined basis demand for diagnostics across the healthcare continuum remained strong in our laps business delivered high single digit growth.
As these shifts instruments are installed validated and come online.
We believe these placements will have a modest positive impact in 2023 and will set us up in 2024 for additional growth.
Our team was steadfast and executing our key growth drivers this quarter.
Our laps business backlog approached normalized levels Emily saw utilization increase.
Turning to our point of care business unit respiratory.
Respiratory revenue declines driven by a reduction in our retail business as expected. Following the end of the COVID-19 public health emergency in May and the continued transition to an endemic stage with insurance companies no longer supporting pre at home COVID-19 tests, including.
Sophia non COVID-19 pull through continued to increase.
And we completed both the Savannah, EUA and slide 10-K, FDA submissions as plans <unk>.
Including 510 case for the instrument and both Rmbp and.
<unk> the the the lesion panels.
Our quick few over the counter test our overall COVID-19 business faced a challenging comp on a year over year basis.
Drilling down into the results from our four business yet first are labs business delivered 9% growth in non respiratory revenue.
And as reported by several other diagnostic companies at the end of the public health emergency had a significant dampening effect.
The growth across all major geographic regions.
Notable global strength and clinical chemistry was driven by expected utilization levels for instrument and a strong integrated instrument placements over the last few years, which also drove solid growth and immuno assay and it's clearly helpful to gross margin.
Molecular COVID-19 test volumes.
This helped to drive double digit year over year growth of our point of care curve with business as.
As many customers shifted testing for symptomatic patients back to antigen tests and more specifically to our Sofia Sars antigen assay.
Instrument demand remains healthy across all regions.
Looking at non respiratory revenue was down 4% year over year due to quarterly variability in our component sales to Beckman BNP.
Execution by our operations team enabled us to produce nearly 10% more instruments.
Then our record breaking first quarter and reduced our instrument backlog in our laps business by approximately 40%.
BNP business, which as a reminder is contracted to be $70 million to $75 million per year.
These efforts enabled us to ship more instruments than previously anticipated in the quarter. As a result are integrated installed base grew 13%.
Our overall Sofia business continues to be strong globally.
With cumulative placements about flat at 87000 instruments in the U S. Non COVID-19, trailing 12 month sales per instrument grew 14% year over year.
Automation increased 20% continue.
Continuing the positive trend that we've seen since implementing our commercial excellent program and launching our features <unk> 7600 integrated system and.
Aside the U S. We're seeing double digit year to date instrument placement growth in Europe , Middle East Africa, and triple digit year to date placement growth in China.
In late 2018.
As these shipped instruments are installed validated income online.
On a small base.
Moreover, we saw a healthy performance from our triage business, which was up 7% compared to last year.
We believe these placements will have a modest positive impact in 2023 and will set us up in 2024 for additional growth.
With particular strength from China, Asia Pacific and Latin America, which is evidence of the cross selling revenue synergies that we have anticipated.
Turning to our point of care business unit.
Respiratory revenue declines driven by a reduction on a retail business as expected.
Our transfusion medicine business was down approximately 3% from this time last year due to continued weakness on our donor screening business.
Following the end of the COVID-19 public health emergency in May and the continued transition to an endemic stage with insurance companies no longer supporting pre at home COVID-19 test, including our quick to you over the counter assess our overall COVID-19 business face to challenging.
Partially offset by strength in immuno hematology.
The donor screening weakness was due to strong revenue in the prior year and a broad broader macro trend of declining blood donations in the United States.
Com on a year over year basis.
However, our strong immuno hematology business, which represents about 70% of our transfusion medicine business unit revenue.
As reported by several other diagnostic companies at the end of the public health emergency had a significant dampening effect on molecular Covid test volumes.
Achieved a 5% year over year improvement in revenue normalizing.
For us this helped to drive double digit year over year growth of our point of care Covid business as.
Normalizing our year to date growth following a soft first quarter.
As many customers shifted testing for symptomatic patients back to antigen tests and more specifically to <unk> assay.
And last our molecular diagnostics business declined as one would expect with sales of our Alere assays declining as the molecular testing market continues to shift from high volume centralized testing.
Looking at non respiratory revenue was down 4% year over year due to quarterly variability in our component sales to Beckman for BNP business, which as a reminder is contracted to be $70 million to $75 million per year.
To more automated decentralized solutions, notably this was partially offset by Savannah, which continued to perform well in the EU with a modest improvement in sales year over year.
Given the products ease of use and industry, leading speed, we are seeing a lot of customer interest and have expanded our reach to more customers across Europe .
Our overall Sophia business continues to be strong globally.
With cumulative placements about flat at 87000 instruments in the U S. Non COVID-19, trailing 12 months out sales per instrument grew 14% year over year.
Following the 2022 currently access launch in Italy, and Austria, we are now placing instruments in France, Germany, Spain, Belgium, and Switzerland I'm.
Side of the U S. We're seeing double digit year to date instrument placement growth in Europe , Middle East Africa, and triple digit year to date placement growth in China.
I am quite encouraged by the positive response spanning has received from leading diagnostics providers across a growing number of markets.
Be it a small base.
Moreover, we saw healthy performance from our triage business, which was up 7% compared to last year.
As I mentioned earlier, we completed both the Savannah, EUA and five 10-K FDA submissions as planned.
With particular strength from China, Asia Pacific and Latin America.
Including <unk> 10-K for the instrument and both RVP for an HFC. These EV lesion panels, the launch of our revolutionary savanna molecular platform.
As evidence of the cross selling revenue synergies that we have anticipated.
Our transfusion medicine business was down approximately 3% from this time last year due to continued weakness on our donor screening business.
As a high priority savanna uses real time Pcr.
<unk> relevance from genomic panels to address a variety of pain points across the diagnostic continuum platform offers speed and flexibility and is easy to use making it suitable for use in multiple customer environments, including physician office labs Emergency Department pharmacies.
Partially offset by strength.
<unk>.
The donor screening weakness was due to strong revenue in the prior year and abroad broader macro trend.
Climbing blood donations in the United States.
Wherever our strong immuno hematology business, which represents about 70% of our transfusion medicine business unit revenue.
<unk> care settings, as well as hospitals and reference labs.
We completed validation of our second low volume savanna cartridge manufacturing line. During Q2 and are currently building inventory in anticipation of Savannah as a launch in the U S.
Achieved a 5% year over year improvement in revenue.
Normalizing our year to date growth following up soft first quarter.
And last hour molecular diagnostics business declined as one would expect with sales of our lire assays declining at the molecular testing market continues to shift from high volume centralized testing.
Following regulatory clearance are initial menu includes our RVP for respiratory viral panel and HFC vesey the lesion panel to be followed throughout 2024 by RVP 11 and.
To more automated decentralized solutions.
<unk> syphilis panel.
Notably this was partially offset by Savannah, which continued to perform well in the EU with a modest improvement in sales year over year.
Our panel for sexually transmitted infections, including chlamydia gonorrhea, mycoplasma genitalia, and trigger months' fashion ounce plus two gastrointestinal panels, one bacterial or viral and a second parasitic panel.
Given the products ease of use and industry, leading speed, we're seeing a lot of customer interest and have expanded our reach to more customers across Europe .
Janus panel that test for for bacterial pathogens.
Knowing the 2022 currently access launch in Italy, and Austria, we are now placing instruments in France, Germany, Spain, Belgium, and Switzerland.
And finally, a vaginitis panel.
Focused our offering on syndromic testing needs to take advantage of the unique features of the Savannah.
<unk> rapid turnaround time simple.
I'm quite encouraged by the positive response standing up so we received from bleeding diagnostics providers across a growing number of markets.
Simple workflow and test flexibility, allowing more clinically relevant information to be generated closer to the patient in a timeframe that can be that actually can affect treatment.
As I mentioned.
On behalf of our customers and shareholders I'm thrilled that the U S. Savannah launch is progressing as the platform is robust with total addressable market is huge.
And the outlook is very exciting.
As the company focused on long term growth we continuously monitor.
<unk> converging trends across the healthcare sector.
Of which I believe will strengthen our position in the diagnostics industry.
<unk> the aging population.
Surge of chronic conditions and diseases as well as emerging infectious diseases. Additionally, the diagnostic industry can play an important role in providing greater access to care and limiting the escalating cost of health care.
We believe that we are strategically positioned to capitalize on these trends we have the right strategy mixed with the powerful combination of our organization and the ability to serve the full diagnostics continuum.
The hospital and lab to clinic.
Our performance in the second quarter demonstrated the strength of our organization as we delivered strong value propositions to support customers across all segments.
Partnering with them to help them solve their most immediate business needs and executing on the initiatives.
That drive meaningful growth and can contribute to measurable and enduring positive impact.
And health outcomes for our customers shareholders and communities our ability to consistently deliver high quality products and services is supported by our deep expertise as a pure play in vitro diagnostics provider.
In May 2023, we passed the one year market, becoming quite our ortho and our integration has thus far yielded better than expected results.
Our culture continues to thrive and evolve as we leverage our strengths and examine opportunities for growth.
While simultaneously advancing our capabilities and improving our day to day operation.
As we pull our two companies together major initiatives are moving forward and we are ahead of schedule on our related cost synergy targets. We are operating as a nimble and agile company that can respond to immediate needs with our industry, leading testing technologies for health care providers around the world without losing.
Focus on the patient or our long term growth strategy.
<unk> identified additional opportunities to optimize the organization.
By improving supplier agreements reducing complexity.
Dreamliner business processes, and workflows and implementing best practices.
Therefore, we've now identified cost synergies of $130 million.
That we expect to realize over three years compared to our prior to our target of the $90 million and we continue to pursue further opportunities.
As an industry leader, we are poised for the next phase of integration that being transformation.
We've mobilized our top tier team members.
Bind with a leading edge industry transformation firm aiming.
Aiming to deliver sustained revenue and margin growth.
<unk> made to our shareholders.
Our strategy hinges on fostering profitable growth opportunities improve cash flow.
And upstream.
Fostering a culture of continuous improvement it.
It is important to note that it's still very early in our transformation journey I look forward to sharing additional details by the end of the year.
Before I turn the call over to Joe to review, our financial performance in greater depth. The team and I are incredibly excited about what's next for quite Delta ortho, we're seizing opportunities and acting decisively.
And were never losing sight of the future of patient care.
Company reached historic highs during the pandemic.
Demonstrating our ability to quickly solve the problems of today.
With the pandemic in the rearview mirror.
We're on our way to demonstrating our agility and nimbleness once again, while driving long term sustainable growth.
Let's turn the call over to Joe to review, our financial performance and guidance for the full year, Joe Okay. Thanks, Doug and good afternoon, everyone.
Before I discuss our financial results for the second quarter I want to remind you that to facilitate our year over year comparison of the company's operating performance all growth rates that I referenced are presented on a supplemental combined basis as if codell and ortho had been combined.
The applicable periods and may be referred to as supplemental combined information.
Starting with the breakdown of revenue on slide seven the demand environment continues to be strong and we delivered another strong quarter on the top line.
Non respiratory revenue grew 4% in constant currency.
$576 million in the second quarter driven by continued.
Brian .
In our labs business unit as.
As well as increase in strengthen our triage product line and a bounce back of immuno hematology.
Excluding our donor screening business, which was a headwind in the quarter as Doug mentioned non respiratory revenue would have been up 7% in constant currency.
Respiratory revenue totaled $89 million in the quarter, including $56 million in Covid related revenue.
Respiratory revenue was softer than expected due to a sharper than expected decline in <unk> related revenue.
Following the end of the public health emergency in May.
Partially offset by a resilient revenue.
In total revenue was down 26% to $665 million and reflecting the strong COVID-19 related revenue in the second quarter of 2022.
The strength of our Covid related revenue a year ago highlights, what we and others in the diagnostic space have been same for several quarters. We believe COVID-19 is transitioning to an endemic state and is continuing to like any other respiratory disease appropriately we know bucket COVID-19 revenue with our other respiratory revenue.
Turning to our quarterly performance by geography on a constant currency basis, and excluding respiratory revenue.
North America revenue declined 2%.
EMEA grew 4%, China grew 26% and our other region, which includes Latin America, and Japan, and other Asia Pac markets grew 9%.
North America, our largest geography by revenue delivered solid revenue in the labs business.
But non respiratory revenue declined.
The previously mentioned weakness from donor screening.
Strengths included both recurring revenues and instruments, leading our major regions and instrument revenue growth contribution.
During the quarter, we made the final $4 million shipment on our previously discussed government contract for quick view at home test.
And we don't anticipate any further government revenue for the remainder of the year.
In the EMEA region solid non respiratory revenue growth was driven by labs immune.
Immuno hematology.
Lab strength was widespread across most major countries in the region, while the immuno hematology growth was driven by a large customer orders in the middle East.
We also saw strong double digit growth in triage placements, which we expect to drive incremental revenue growth in future quarters.
And our China region, which makes up about 10% of our total company revenue non respiratory growth of 26% was driven by broad strength in labs hospital demand continued to be strong throughout the quarter driving growth above the rate we realized in Q1.
Which had benefited from the surge of demand early in the year. Following the end of COVID-19, Lockdowns at the end of 'twenty two.
Within point of care, we continued to drive double digit growth of our triage products in our Sofia year to date revenue was close to double R. 22 full year revenue following the launch of Sofia, two and strong instrument placements in the quarter. Both of these accomplishments are clear demonstrations of revenue cross selling synergies.
Turning to our Q2 non respiratory revenue by category recurring revenue, which includes reagents service and other consumables grew 4%.
Excluding our donor screening business recurring revenue would've been up 6%.
Instrument revenue grew 10% as instrument demand was robust and we've worked down our open labs instrument orders by approximately 40% to 300 instruments from $5 <unk> at the end of Q1 and $6 50 at the end of 'twenty two.
So while global supply chain challenges appear to be easing. We don't believe that were fully resolved and customer readiness. During the summer months, we'll be eliminate factor in the near term. We continue to expect elevated open orders to modestly persist into early 'twenty four as we work toward our goal of a normalized 105.
Open orders.
Now turning to slide eight I'd like to comment on our second quarter financial performance below revenue versus the prior year again on a supplemental combined basis.
Gross profit margin for the quarter was $45 six a bit lighter than our expectation due to product mix, including the strong instrument revenue as we worked down our labs instrument open orders and lower than expected COVID-19 related revenue due to the end of the public health emergency.
Moving down the P&L R&D expense increased about $1 million sequentially.
$3 million higher than expected due to the Savannah FDA regulatory submissions.
Sales marketing and administrative expenses expenses were down $23 million sequentially, reflecting execution on cost synergies and a reduction in variable expenses.
We expect sales marketing and administrative expenses to be flat to slightly down in Q3, and Q4 as compared to Q2.
Adjusted EBITDA also declined year over year to $113 3 million slightly ahead of our expectations due to the strong revenue.
Adjusted EBITDA margin contracted year over year to 17% slightly below our expectations due to product mix, including strong instrument revenue and lower than expected COVID-19 related revenue due to the end of the public health emergency.
As well as the $3 million higher than expected R&D expense due to the Savannah FDA regulatory submissions.
Net interest expense for the period was $36 million, an increase of $7 million versus the prior year as anticipated due to the increase in the average outstanding debt balances related to the combination.
And as a reminder, we have swaps in place that secure approximately 70% of our term loan at a fixed rate for the life of alone providing for an all in interest rate after the effect of our swaps of approximately five 6%.
Our provision for income taxes was $5 million compared to $63 million from the prior year period. This represents a second quarter adjusted tax rate of 23, 4% down from the prior year period due to discrete items.
Our adjusted earnings per fully diluted share for the second quarter was 26 cents compared to $2 12 in the second quarter of 'twenty two on the supplemental combined basis. The decrease in EPS was again driven by an exceptionally strong prior year period, and Covid transitioning to an endemic state.
The higher than expected R&D expense due to the Savannah, FDA regulatory submissions negatively impacted our EPS in the quarter by <unk> <unk>.
Now turning to cash flow and balance sheet on slide nine.
In the second quarter on a GAAP basis cash outflow from operating activities was $31 million is in line with our expectations.
After funding $49 million in Capex, and adding back $16 million in integrated integration related capital expenditures and $33 million in acquisition integration and other costs.
We estimate adjusted free cash flow to be a negative $3 million for the quarter again in line with our expectations.
In terms of capital deployment in the second quarter.
We used $112 million of cash to make our final $40 million payment to Abbott for the $680 million purchase of the Alere cardio metabolic assets.
And we paid down $72 million of our term debt our debt paydown.
$20 million more than the contractual requirement of our term loan as we take a key step towards reducing our leverage while we did not buyback any shares in the quarter, we intend to maintain a balanced and opportunistic approach to share repurchases. While also continuing to prioritize our debt paydown going forward.
We ended the quarter with cash cash equivalents in marketable securities of 248 million and total debt of $2 5 billion.
We ended with two eight times net debt to EBITDA on a supplemental combined basis.
And as Covid related revenue was declined due to the transition from a pandemic to an endemic or our leverage has modestly increased but we expect leverage to finish the year slightly down from where we are now.
Deleveraging is a top priority with our goal to be at or below two times net leverage by the end of 'twenty four while maintaining flexibility for strategic M&A opportunities.
Okay.
Now turning to our fiscal year 'twenty three guidance on slide 10.
Now turning to cash flow and balance sheet on slide nine in.
First I would like to provide some broader context on our outlook labs instrument supply issues are expected to continue to alleviate as we move through the second half of the year, which along with the continued recovery in China are expected to drive high single digit non respiratory growth in labs.
In the second quarter on a GAAP basis cash outflow from operating activities was $31 million is in line with our expectations.
After funding $49 million in Capex, and adding back $16 million in integrated integration related capital expenditures and $33 million in acquisition integration and other costs.
The end of the public health emergency cause a meaningful decline in the retail COVID-19 market as well as molecular.
We estimate adjusted free cash flow to be a negative $3 million for the quarter again in line with our expectations.
Human advantage and testing has picked up share in the professional market from a competitive molecular systems.
In terms of capital deployment in the second quarter.
Due to these two headwinds on the cobot market, our Covid outlook has come down.
We used $112 million of cash to make our final $40 million payment to Abbott for the $680 million purchase of the Alere cardio metabolic assets.
In light of these dynamics, we are updating our fiscal 'twenty three full year guidance as follows.
Total revenue of $2 88 to $3 8 billion.
And we paid down $72 million of our term debt our debt paydown was $20 million more than the contractual requirement of our term loan as we take a key step towards reducing our leverage while we did not buyback any shares in the quarter, we intend to maintain a balanced and opportunistic approach to share repurchases.
Compared to our prior guidance of $2 87 to $3 8 billion.
Breaking this down a little further we are raising our non respiratory revenue guidance to the high end of our prior guidance, while lowering our respiratory guidance.
Non respiratory revenue is expected to grow five to six 5% on a constant currency basis.
While also continuing to prioritize our debt paydown going forward.
We ended the quarter with cash cash equivalents in marketable securities of 248 million and total debt of $2 5 billion.
Two to two 7% to 231 billion.
From our prior guidance of four five to six 5% on a constant currency basis.
We ended with two eight times net debt to EBITDA on the supplemental combined basis.
226 to $2 31 billion.
We now have a respiratory revenue guide of 610 to 775 million.
And as Covid related revenue was declined due to the transition from a pandemic. It endemic or our leverage has modestly increased but we expect leverage to finish the year slightly down from where we are now.
Including Covid revenue of 300 to 400 million.
Compared to our prior guide of $6 $10 million to $875 million, including Covid revenue of $3 to $500 million.
The leveraging is a top priority with our goal to be at or below two times net leverage by the end of 'twenty four while maintaining flexibility for strategic M&A opportunities.
And it's.
Interesting to note that in the second half of 'twenty, three we expect that more than 93% of our cobot revenue forecast is in the professional market.
Okay.
Okay.
Now turning to our fiscal year 'twenty three guidance on slide 10.
We now.
Full year gross margins to be at the low end of our prior expectations of low to mid fifties due to product mix, including higher instrument revenues from the faster than expected Giuliana labs instrument open orders.
First I would like to provide some broader context on our outlook labs instrument supply issues are expected to continue to alleviate as we move through the second half of the year.
Adjusted EBITDA margin expected of 26, 9% to 27, 7%.
Along with the continued recovery in China are expected to drive high single digit non respiratory growth in labs.
In the range of $800 million to $830 million compared to our prior guidance of $8 15 to $8 65.
The end of the public health emergency cause a meaningful decline in the retail COVID-19 market as well as molecular.
And despite the reduction in our guidance for higher margin Covid related revenue, we are offsetting a full P&L impact of the revenue drop with expense reductions.
Even advantaged testing has picked up share in the professional market from a competitive molecular systems.
Due to these two headwinds on the cobot market, our Covid outlook has come down.
Adjusted diluted EPS is now expected to be in the range of $4 85 to $5 30.
In light of these dynamics, we are updating our fiscal 'twenty three full year guidance as follows.
Total revenue of $2 eight eight to $3 8 billion.
Compared to our prior guidance of $5 15 to $5 70.
Compared to our prior guidance of $2 87 to $3, one 8 billion.
Okay.
In addition, I'd like to discuss the assumptions that covered last quarter that may be helpful for modeling purposes at current rates currency translation.
Breaking this down a little further we are raising our non respiratory revenue guidance to the high end of our prior guidance, while lowering our respiratory guidance.
<unk> is expected to be about neutral to full year sales and adjusted EBITDA with a higher FX impact on non respiratory revenue.
Non respiratory revenue is expected to grow five to six 5% on a constant currency basis.
As previously discussed and consistent with prior quarters or prior years.
First and the fourth quarters are seasonally the strongest quarters of the year.
Two to $2 7 million to $2 three 1 billion.
Net interest expense continues to be expected in the range of $145 million to $150 million for the year.
Up from our prior guidance of four 5% to six 5% on a constant currency basis to.
The $2 two six to $2 31 billion.
We continue to expect our full year adjusted tax rate of approximately 23, 5%.
We now have a respiratory revenue guide of $6 10 to 775 million include.
We continue to expect adjusted free cash flow to be at the low end at the 50% to 65% of adjusted EBITDA, which translates into more than 100% of adjusted net income and.
Including Covid revenue of $300 million to $400 million compared to our prior guide of $6 $10 million to $875 million, including Covid revenue of $3 to $500 million.
And full year diluted weighted average share count is $67 2 million.
And it's <unk>.
So with that I'll turn the call back over to Doug to make a few summary comments.
Interesting to note that in the second half of 'twenty, three we expect that more than 93% of our cobot revenue forecast is in the professional market.
Thanks, Joe and conclusion of the second quarter demonstrated the strength of our combined organization.
We now expect full year gross margins to be at the low end of our prior expectations of low to mid fifties due to product mix, including higher instrument revenues from the faster than expected Julian on the labs instrument open orders.
Our solid financial results driven by our labs business unit and triage.
We raised non respiratory revenue guidance to the high end of our prior guide.
While lowering our risk purely guidance to the low end of our prior guidance.
Adjusted EBITDA margin.
We have now identified cost synergies of $130 million that we expect to realize over three years.
<unk> of 26, 9% to 27, 7%.
In the range of $800 million to $830 million compared to our prior guidance of $8 15 to $8 65.
As we are making steady progress across the organization.
Proving the efficiency of the business paying down debt generating cash and being good stewards of shareholder capital, we're laying the necessary groundwork for our transformation to an organization that is positioned for long term top line and.
And despite the reduction in our guidance for higher margin Covid related revenue, we are offsetting the full P&L impact of the revenue drop with expense reductions.
Adjusted diluted EPS is now expected to be in the range of $4 85 to $5 30.
And bottom line growth now.
Now, let's open the line for Q&A.
Compared to our prior guidance of $5 15 to $5 70.
We will now begin the Q&A session.
If you would like to ask a question. Please press star followed by one of your Touchtone keypad.
Okay.
In addition, I'd like to discuss the assumptions that covered last quarter that may be helpful. For modeling purposes at current rates currency translation is expected to be about neutral to full year sales and adjusted EBITDA with a higher FX impact on non respiratory revenue.
If for any reason you would like to turn that question. Please press star followed by two.
To ask a question please star one.
As a reminder, if you are using a speaker phone. Please remember to pick up your handset before asking a question.
As previously discussed and consistent with prior quarters or prior years.
We will pause briefly to allow questions to generate in Q.
And the fourth quarters are seasonally the strongest quarters of the year.
The first question comes from the line of Patrick Donnelly with Citi. Please proceed.
Net interest expense continues to be expected in the range of $145 million to $150 million for the year.
Hey, there you got Jason on for Patrick maybe first on China performance in the quarter growing 26% ex Covid.
We continue to expect our full year adjusted tax rate of approximately 23, 5%.
We continue to expect adjusted free cash flow to be at the low end of the $50 to 65% of adjusted EBITDA, which translates into more than 100% of adjusted net income and.
How do things trend in the country throughout the quarter.
You see any changes in demand as the quarter went on.
Is double digit ex COVID-19 growth still how you're thinking about the guide there for the year.
Full year diluted weighted average share count is $67 2 million.
Although we saw was the stabilization of the business there and we had a bit of a surge in the first quarter I think what youre seeing.
So with that I'll turn the call back over to Doug to make a few summary comments.
In Q2 is more of a return to normalcy.
Thanks, Joe in conclusion, the second quarter demonstrated the strength of our combined organization.
What would you add Joe in terms of the actual number of yeah.
The solid financial results driven by our labs business unit and triage.
No change in expectations there for the full year, we're still expecting high single digits total revenue growth in <unk> and.
We raised non respiratory revenue guidance to the high end of our prior guide.
In high teens.
Full year revenue growth excluding Sars.
While lowering our risk purely guidance to the low end of our prior guide.
Got it Okay. That's helpful. And then maybe just on the Savannah manufacturing how has that been ramping how should we be thinking about production capacity relative to initial demand as.
We have now identified cost synergies of $130 million that we expect to realize over three years.
As we are making steady progress across the organization.
As well as the automated production line coming online next year.
Proving the efficiency of the business paying down debt generating cash and being good stewards of shareholder capital, we're laying the necessary groundwork for our transformation to an organization that is positioned for long term top line and.
That's a great question, we're actually at the Phase now where we're stocking.
Stocking instruments.
In support of what we anticipate to be a reasonably good launch.
Assuming that we're in market for this upcoming respiratory season, so again.
And bottom line growth now.
Now, let's open the line for Q&A.
We're already at this stage from an instrument.
We will now begin the Q&A session.
Position that we feel like we can address the upcoming launch and on the cartridge side as I mentioned.
If you would like to ask a question. Please press star followed by one of your Touchtone keypad.
If for any reason you would like to remove that question. Please press star followed by two.
Just finished standing up our second low volume manufacturing line for the crushers.
To ask a question press star one.
As a reminder, if you are using a speaker phone. Please remember to pick up your handset before asking a question.
Yes.
Both clinical trials and launches.
And that's going well too so I think we're in really good shape from a supply chain and.
We will pause briefly to allow questions to generate in Q.
Launch perspective.
The first question comes from the line of Patrick Donnelly with Citi. Please proceed.
Got it thank you.
Hey, there you got Jason on for Patrick maybe first on the China performance in the quarter growing 26% ex Covid.
Thank you.
Okay.
The next question comes from the line of Angie.
How do things trend in the country throughout the quarter.
Andrew Cooper.
You see any changes in demand as the quarter went on.
With Raymond James Please proceed.
Is double digit ex COVID-19 growth still how you're thinking about the guide there for the year.
Hi, everyone. Thanks for the question, let me first I just want to talk a little bit about adjusted EBITDA here in the market.
Although we saw was the stabilization of the business there and we had a bit of a surge in the first quarter I think what youre seeing.
Margins moving a little bit lower I think the conversations we had had about Colgate and respiratory prior was that there isn't really worked closer to the consolidated average you talked about some some expense offsets as well.
In Q2 is more of a return to normalcy.
What would you add Joe in terms of the actual number of yeah.
No change in expectations there for the full year, we're still expecting high single digits total revenue growth in <unk> and.
We do see that margin go on Lori can you just help me kind of think through some of the moving parts there and maybe why we are seeing more of those synergies and more of those cost offsets, helping helping dropdown.
In high teens.
Full year revenue growth excluding <unk>.
The drop down a little bit more.
Yes, Andrew it's Joe.
Got it Okay. That's helpful. And then maybe just on the Savannah manufacturing how has that been ramping how should we be thinking about production capacity relative to initial demand as.
Yes.
So there are two big changes too.
To the guide.
On the revenue side, we are taking the non respiratory revenue guide up to the upper end of the range and that's really driven by the strong results. We're seeing on the labs business and the continued success were seeing unwinding that instrument backlog.
As well as the automated production line coming online next year.
That's a great question, we're actually at the Phase now where we're stocking.
Stocking instrument.
In support of what we anticipate to be a reasonably good launch.
In the quarter and then early in this Q3.
Assuming that we're in market for this upcoming respiratory season, so again.
A lot of other diagnostic companies that have already reported we are seeing some softness on the COVID-19 revenue side.
We're already at this stage from an instrument.
Those are the areas, where we're seeing that softness on code are particularly on the molecular side, where that testing is moving to antigen and on the retail side, where it seems that the asymptomatic testing as it does not happening as much as it was last year and earlier this year.
Position that we feel like we can address the upcoming launch and on the cartridge side as I mentioned.
Just finished standing up our second low volume manufacturing line for the crushers.
Yes.
For both clinical trials and launches.
So we did bring down the revenue guide there. So there is definitely a margin impact to two those two things that I just mentioned as we drill down.
And that's going well too so I think we're in really good shape from a supply chain and.
Launch perspective.
Got it thank you.
Lapsed backlog faster than we had expected earlier in the year.
It's a good thing.
Okay.
Because we're producing more instruments and we're getting more instruments out to our customers and thats going to drive more recurring revenue in the future.
Thank you.
Okay.
The next question comes from the line of Andrew Cooper.
But in the short term is going to drive margins down a bit as we drive more instrument revenue, which had it just has lower margins.
With Raymond James Please proceed.
Hi, everyone. Thanks for the question.
Significantly lower margins than the recurring reagent revenue.
Maybe first I just want to talk a little bit about adjusted EBITDA here.
And the margins moving a little bit lower I think the conversations we had had about Colgate and respiratory prior was that there isn't really worked closer to the consolidated average you talked about some some expense offsets as well, but we do see that margin go on Lori can you just help me kind of think through some of the moving parts there.
And then on the Covid revenue.
Most of the commentary we made about the margins approximating. The overall total company margin were related to the government contract that we fulfilled in Q1 and early in Q2, but as you look at the Covid margins for retail and professional they are still pretty strong margins relative to.
Why we are seeing more of those synergies and more of those cost offset helping helping dropdown.
To the rest of our product mix and so by pulling down that equivalent revenue in the second half of it is going to have an impact.
<unk> limit the drop down a little bit more.
Yes, Andrew it's Joe.
Yes.
And if you work through the math.
So there are two big changes too.
I'm sure we all do this after the call if you work through the math.
To the guide.
The midpoint of the revenue drop on the guidance and then the EBITDA and EPS drop you will see that we did actually offset some of the margin impact with cost reductions.
On the revenue side, we are taking the non respiratory revenue guide up to the upper end of the range and that's really driven by the strong results. We're seeing on the labs business and the continued success were seeing unwinding that instrument backlog, but.
To soften that.
EBITDA and EPS impact on the bottom line.
In the quarter and then early in this Q3 and like a lot of other diagnostic companies that have already reported we are seeing some softness on the COVID-19 revenue side.
Okay, Great. That's helpful. And then maybe just one more one we got a lot on the in the quarter just around the triage business and some of the moving parts here in the U S. Specifically with the recall, obviously it sounds like a really strong quarter. There overall, so maybe just help us.
So those are the areas, where we're seeing that softness on code are particularly on the molecular side, where that testing is moving to antigen.
And on the retail side, where it seems that the asymptomatic testing as it does not happening as much as it was last year and earlier. This year. So we did bring down the revenue guide there. So there is definitely.
To isolate the impact how we should think about it for this quarter and into the future and then.
Some of the key factors, maybe helping drive that growth with the cross selling and international market.
Yes.
I'll start with the recall part of the question.
Only a margin impact to two those two things that I just mentioned as we drill down the <unk>.
Just point out that we're talking about a very small number of cases.
<unk> backlog faster than we had expected earlier in the year.
It's a small number of skus that were affected and so the financial impact as what happened with.
As a good thing.
Because we're we're producing more instruments and we're getting more instruments out to our customers and thats going to drive more recurring revenue in the future.
It's de Minimis.
More than offset by the growth that we're seeing particularly ex U S.
In the short term is going to drive margins down a bit as we drive more instrument revenue, which had it just has lower margins.
Of the triage business.
And by the way Andrew Treehouse did have a nice quarter up and up high single digits in the quarter and so.
Significantly lower margins than the recurring reagent revenue.
And then on the Covid revenue.
Up nicely sequentially from Q1, so we are starting to see those nice cross selling opportunities, particularly outside of the U S, which is driving that growth and that's going to drive a nice full year growth from the triage business.
Most of the commentary we made about the the margins approximating. The overall total company margin were related to the government contract that we fulfilled in Q1.
And early in Q2, but as you look at the Covid margins for retail and professional they are still pretty strong margins relative to the rest of our product mix and so by pulling down that equivalent revenue in the second half of it is going to have an impact.
Okay I'll stop there. Thank you.
Thank you.
The next question comes from the line of Alex Nowak with Craig Hallum Capital Group. Please proceed.
And if you work through the math.
Okay, great. Good afternoon, everyone I know youre adjusting the respiratory guidance here today, but we are entering the second half. So I got to ask the question anyway. Just how are you thinking about the flu season.
I'm sure we all do this after the call if you work through the math.
Through the midpoint of the revenue drop on the guidance and then the EBITDA and EPS drop you will see that we did actually offset some of the margin impact with cost reductions.
Australia flu season that they are going through right. Now. We're also hearing news about another COVID-19 bearing potential floating around we're seeing positivity spiking. So what are you hearing out there in the channel and then just remind us how much COVID-19 inflow inventory results may still sitting out there.
To soften that.
<unk> EBITDA and EPS impact on the <unk>.
Online.
Okay, Great. That's helpful. And then maybe just one more one we got a lot on the in the quarter just around the triage business and some of the moving parts here in the U S. Specifically with the recall, obviously it sounds like a really strong quarter. There overall, so maybe just help us.
Yes.
On flu. This is the same answer.
At this time of year that I've been giving I think for the last 14 years and that is.
We see correlation between southern Hemisphere, and northern Hemisphere, and I think when I last saw that we had looked at the last 20 or 25 years or something.
Icelanders impact how we should think about it for this quarter and into the future and then.
Some of the key factors, maybe helping drive that growth with the cross selling and international market.
The R squared between the two.
Is pretty high but it is not.
Yes.
So it's not causing this not necessarily cause and effects. So.
I'll start with the recall part of the question.
Just point out that we're talking of a very small number of cases across a small number of skus that were affected and so the financial impact as what happened with.
<unk>.
I do think that we're hearing from the government some concern about what's going to happen in the upcoming respiratory season.
But what I would normally say Alex is.
It's de Minimis.
More than offset by the growth that we're seeing particularly ex U S.
I never know when it's going to start and stop.
So do I believe that we'll see in <unk>.
Influenza season this year that is.
Of the triage business.
More traditional in terms of size.
And by the way Andrew tree as did have a nice quarter up and up high single digits in the quarter and so.
So I just can't predict how much of that is going to occur in the fourth quarter and how much of that.
Up nicely sequentially from Q1, so we are starting to see those nice cross selling opportunities, particularly outside of the U S, which is driving that growth and that's going to drive a nice full year growth from the triage business.
For the first quarter.
In terms of cobalt inventory.
Oh, Yes go ahead.
<unk> sales.
Have been reasonable because for for.
Okay I'll stop there. Thank you.
For most of the inventory that would have been shifted distribution. That's the product that gets shipped into the professional segment.
Thank you.
The next question comes from the line of Alex Nowak with Craig Hallum Capital Group. Please proceed.
And so I am not.
I'm not thinking that we are sitting with a lot of inventory out there at the moment.
Okay, great. Good afternoon, everyone I know youre adjusting the respiratory guidance here today, but we are entering the second half. So I got to ask the question anyway. Just how are you thinking about the flu season.
I can.
So im looking ahead of distributors inventory is down quite a bit from prior year and its also down from from Q1. So we're looking at pretty low levels of distributor inventory of cars in the U S. Right and then when we see there our sales report we know that they shipped.
<unk>, Australia flu season that they are going through right. Now. We're also hearing news about another COVID-19 bearing potential floating around we're seeing positivity spiking. So what are you hearing out there in the channel and then just remind us how much COVID-19 and flu inventory results may still sitting out there.
And we.
Suspect that will happen as is typical.
Yes.
On flu. This is the same answer.
Is that during the respiratory season that same set of distributors, who will reorder before we get too far into the fourth quarter, sometimes that occurs earlier.
At this time of year that I've been giving I think for the last 14 years and that is.
We see correlation between southern Hemisphere, and northern Hemisphere, and I think when I last saw that we had looked at the last 20 or 25 years or something.
As early as late third quarter, but we're not modeling at the moment. So that is true for both COVID-19 and for flow.
The R squared between the two.
Okay very helpful. And then maybe going back over to savanna can you remind us how the initial launch of Savannah in Europe , what where you're seeing those competitive conversions happen like you outlined at the analyst day share gains to take place and how has that changed the initial U S game plan once we get the approval.
Is pretty high but it's not.
It's not causing this not necessarily cause and effects. So.
I do think that we're hearing from the government some concern about what's going to happen in the upcoming respiratory season.
Well I think.
But what I would normally say Alex is.
<unk>.
It's a bit of foreshadowing weighing on what we might expect.
I never know when it's going to start and stop.
So do I believe that we'll see in.
The competitors that we saw.
And influenza season. This year that is more traditional in terms of size I think so I just can't predict how much of that is going to occur in the fourth quarter and how much of that remained for the first quarter.
Based on European feedback.
It might be vulnerable, where indeed, the same two competitors.
And John they are quite well the issues that are reported in Europe , we see as being applicable here in the states to show.
In terms of cobalt inventory.
Oh, Yes go ahead.
Particularly with respect to the respiratory launch.
<unk> sales.
<unk> been reasonable because for for.
We are in.
Really good shape here.
For most of the inventory that would have been shifted distribution thats the product that gets shipped into the professional segment.
And for HSV Vesey.
That's a product that's not a huge market, but we already do quite well.
And so I am not.
Yeah.
I'm not thinking that we are sitting with a lot of inventory out there at the moment.
Alright, I appreciate the update thanks.
There has not been more specific I'm looking ahead as distributors inventory is down quite a bit from prior year and it is also down from from Q1. So we're looking at pretty low levels of distributor inventory of Sars in the U S. Right and then when we see there our sales report we know that they shipped.
Thank you.
The next question comes from the line of Jack Meehan with Nephron Research. Please proceed.
Thank you good afternoon.
Joe So Joe EBITDA forecast for the.
For the year, the EBITDA forecast $800 million to $830 million can you talk about the pacing in the back half I'm getting Jeff <unk> needs to be over 300 million or so is that the magnitude of the step up you are looking for and just what drives that.
And we.
Suspect that will happen as is typical.
Is that during the respiratory season that same set of distributors will reorder before we get too far into the fourth quarter, sometimes it occurs earlier.
As early as late third quarter, but we're not modeling at the moment. So that is true for both COVID-19 and for flow.
I don't know that its that steep.
Jack Hang on one second let me just pull up the file.
Okay very helpful. And then maybe going back over to savanna can you remind us how the initial launch savanna in Europe what.
Qualitatively I guess it is a pretty big step up in the fourth.
It is it is it is a big step because sequentially. We've been saying Q2 was our lightest revenue quarter and that is going to be true Q3 will step up sequentially Q3 will step up sequentially and then Q4, we will step up quite a bit with the respiratory season. So yes.
What are you seeing those competitive conversions happen.
Wind at the analyst day, the share gains to take place and how has that changed the initial U S game plan once we get the approval.
Well I think.
In cardiovascular frankly, yes.
It's a bit of foreshadowing.
From a fourth quarter steps up a little bit more willing to.
You might expect.
The competitors that we saw.
So fourth quarter typically is.
Based on European feedback.
Our second biggest quarter.
Across the combined business.
Be vulnerable.
Indeed, the same two competitors.
Remember also Jack in addition, you've got we're going to have a.
And John they are quite well the issues that.
Decent amount of cost synergies starting to hit the P&L. So your opex number will be coming down quite a bit if youre comparing to Q4 last year.
Our reported in Europe , we see as being applicable here at stage two so.
To have quite a bit of a nice step down in opex year over year.
Particularly with respect to the respiratory launch.
I think we are in.
Okay.
Good shape here in the U S and for HSV.
And then another one on Savannah so.
It's good to see the submissions are in.
That's a product that's not a huge market, but we already do quite well.
When do you pencil in now and approval for 500 10-K and can you just tell us what the second half guide for respiratory includes for savanna sales.
Alright, I appreciate the update thanks.
Thank you.
I'll, let Joe answer the second part of the question. The first part of the question is.
The next question comes from the line of Jack Meehan with Nephron Research. Please proceed.
Traditionally once we make.
Thank you good afternoon.
Submission to the SBA and they are under active review, we don't comment any further so I think the first part of your question was asking me to forecast when we thought we would get approval.
Joe So the.
EBITDA forecast for the.
For the year, the EBITDA forecast $800 million to $830 million can you talk about the pacing in the back half I'm getting Jeff <unk> needs to be over $300 million or so is that the magnitude of the step up you're looking for and just what drives that.
I will.
Do that.
Obviously, we have ongoing dialogue, we have a number of things.
As part of the process, one of which we can discuss.
While while the products are under active review.
I don't know that its that steep.
Yes on the magnitude jacket. There is no change from what we've said the last.
Jack Hang on one second let me just pull up the file.
Quarter, or maybe two quarters that the.
Qualitatively I guess it is.
A pretty big step up in the fourth quarter. It is youre right. It is it is a big step because sequentially.
The Savannah revenue that's in the guide is less than 1% of total revenue.
It's.
We've been saying Q2 is our lightest revenue quarter and that is going to be true Q3 will step up sequentially Q3 will step up sequentially, and then Q4 will step up quite a bit with the respiratory season. So yes.
It is not a big number.
It's been largely fee.
Other way of saying that.
Okay.
Just be.
Be clear just given we're still waiting for the UA in the 10-K or the sales baked in for savanna in the back half just all from <unk>.
In cardiovascular frankly, yes.
In the fourth quarter stepped up a little bit more willing to.
So fourth quarter typically is.
Europe .
Our second biggest quarter.
That's a bit of mix, obviously, the larger as the European.
Across the combined business.
But remember also Jack in addition, you've got we're going to have.
And ex U S sales.
But we do expect.
Decent amount of cost synergies starting to hit the P&L. So your opex number will be coming down quite a bit if youre comparing to Q4 last year, when youre going to have quite a bit of a nice step down in opex year over year.
<unk> sales in the fourth quarter I think I understand.
Okay excellent. Thank you.
Thank you.
The next question. The next question comes from the line of Casey Woodring with Jpmorgan. Please proceed.
Okay.
And then another one on Savannah so.
Hi, Thanks for taking my question. So maybe just picking up piggybacking off of Jack's question looks like the implied back half EBITDA margin is something around 29% to 30% can you just walk us through the puts and takes there on what would get you to the low end and the high end of the range that you gave today and I know, it's tough to run rate the second half margins given the annual strong.
It's good to see that submissions are in.
When do you pencil in now and approval for 500 10-K and can you just tell us what the second half guide for respiratory includes for savanna sales.
I'll, let Joe answer the second part of the question. The first part of the question is.
Fourth quarter, but maybe can you just talk about what the right jump off point would look like for 2020 for margins.
Traditionally once we make a submission to the SBA and they are under active review.
Yes, I can answer.
So the last question first.
Don't comment any further so I think the first part of your question was asking me to forecast when we thought we would get approval.
Casey on the and I assume you're.
Youre talking about well, let me I'll speak to gross margins.
As I said on the call we are going to trend to the low end of the of the previously communicated range of.
I want to.
To do that.
Obviously, we have ongoing dialogue, we have a number of things.
Low to mid fifties.
All of those reasons I mentioned earlier.
As part of the process map, one of which we can discuss.
The drill down of the lapsed backlog, creating more instrument revenue and less COVID-19 revenue than we originally thought.
While while the products are under active review.
Yes on the magnitude jacket. There is no change from what we've said the last.
So we will be at the low end.
<unk>.
Quarter, or maybe two quarters that the.
I still think that the relevant.
The Savannah revenue that's in the guide is less than 1% of total revenue.
Long term range for us is that low to mid fifties.
I need to give this answer but it's a little too early to talk about 24, because there's so many moving moving variables for 'twenty four.
It's.
It is not a big number.
It's been largely fever.
Other way of saying that.
So I'll just reiterate that we still believe that the.
Okay.
The appropriate gross margin range for us is that low to mid <unk> and as you know.
Just to.
To be clear just given we're still waiting for the UA in <unk> 10-K, or the sales baked in for savanna in the back half just all from <unk>.
What's going to move us within that range, it's going to be.
The pace of.
Europe .
Cost synergy achievement as well as the slope of the Savannah revenue ramp and how fast that goes up because as we've said many times.
That's a bit of mix, obviously, the larger as the European.
And ex U S sales.
But we do expect.
<unk> sales in the fourth quarter on the United States.
And we've talked about with you.
The early launch of Savannah in the U S is going to it's going to it's going to be a headwind to margins.
Okay excellent. Thank you.
Thank you.
Until we get we really get that high volume line up and running at some point in 'twenty, four and Thats when the margins will start to get.
The next question. The next question comes from the line of Casey Woodring with Jpmorgan. Please proceed.
Accretive.
Hi, Thanks for taking my question. So maybe just picking up piggybacking off of Jack's question looks like the implied back half EBITDA margin is something around 29% to 30% can you just walk us through the puts and takes there on what would get you to the low end and the high end of the range that you gave today and I know, it's tough to run rate the second half margins given the annual strong.
And then as far as your first question I think it's a similar answer on where we end up in the range.
<unk>.
The EBITDA that we provided today, it's going to be.
It is going to hinge on how much more of the.
The labs backlog, we can drill down and drive more labs growth.
Fourth quarter, but maybe can you just talk about what the right jump off point would look like for 2020 for margins.
What exactly does the respiratory season look like and where does that land in the range.
Yes, I can answer.
So the last question first.
And then how fast we can we can achieve cost synergies.
Casey on the and I assume.
Youre talking about.
I'll speak to gross margins.
This year versus first half next year.
As I said on the call we are going to trend to the low end of the of.
Got it that's helpful. And then maybe just one follow up.
Of the previously communicated range of.
So it looks like the labs business beat the street by more than $30 million here into Q.
Low to mid fifties.
Of those reasons I mentioned earlier.
But just looking at the non respiratory guide for the year it looks like its only going up $5 million.
The drill down of the lapsed backlog, creating more instrument revenue and less COVID-19 revenue than we originally thought.
Can you maybe just talk about some trends in the non respiratory business and then labs for the back half of the year. Thank you.
So we will be at the low end.
Sure.
I still think that the relevant.
Yes, I think the two big variables here no surprise, we've talked about both the things already is China.
Long term range for us is that low to mid fifties.
The continued recovery there throughout the year and then the.
I need to give this answer but it's a little too early to talk about 24, because there's so many moving moving variables for 'twenty four.
The instrument back quarter drill down and how fast that happens in net debt.
Perhaps I'll just reiterate that we still believe that the.
That creates a little bit of variability.
I wouldn't say Casey that we're probably being a little bit.
The appropriate gross margin range for us is that low to mid <unk>.
With the with the guide on the non respiratory non respiratory.
Whats going to move us within that range, it's going to be.
Because you're right.
The pace of.
At the midpoint $105 million.
Cost synergy achievement as well as the slope of the Savannah revenue ramp and how fast that goes up because as we've said many times.
And basically the other variable worth considering is the speed with which our field service engineers install the instruments and the speed with which the customer actually.
And we've talked about with you.
Validates and gets the.
The early launch of Savannah in the U S is going to it's going to it's going to be a headwind to margins.
Instrument and assay as to what they called test of record.
Thats the variable and.
Until we get we really get that high volume line up and running at some point in 'twenty, four and Thats when the margins will start to get.
So when you look at these installations at this point moving forward.
The biggest gain from a revenue and margin perspective, obviously going to incur in 2024.
Accretive.
And then as far as your first question I think it's a similar answer on where we ended up in the range of.
So that's kind of a variable that we're looking at and I think we have been prudent we certainly haven't ever called it.
<unk>.
The EBITDA that we provided today, it's going to be.
Got it that's helpful. Thanks, guys.
It is going to hinge on how much more of the.
Thank you.
Thank you.
The labs backlog, we can drill down and drive more labs growth.
There are no additional questions at this time.
Now I'll hand, it back to Doug for closing remarks.
What exactly does the respiratory season look like and where does that land in the range.
Thank you I want to thank everybody for your great questions in fact, I would just.
And then how fast we can we can achieve cost synergies.
They were the right questions and.
On behalf of our entire management team I want to thank you for your continued support and interest in quite the ortho now. This is a journey for sure and we look forward to sharing our journey with you.
This year versus first half of next year.
Got it that's helpful. And then maybe just one follow up.
So it looks like the labs business beat the street by more than $30 million here into Q.
But just looking at the non respiratory guide for the year it looks like its only going up $5 million.
That concludes today's conference call. Thank you you may now disconnect your lines.
Can you maybe just talk about some trends in the non respiratory business in the labs for the back half of the year. Thank you.
Yes, I think the two big variables here no surprise, we've talked about both defending already is China.
The continued recovery there throughout the year and then the fact, the instrument back quarter drill down and how fast that happens.
That creates a little bit of variability.
I wouldn't say Casey that we're probably being a little bit.
With the with the guide on the non respiratory non respiratory.
Because you're right.
At the midpoint $105 million.
The other variable worth considering is the speed with which our field service engineers install the instruments and the speed with which the customer actually.
Validates and gets the.
Instrument and assay as to what they call test of record.
Thats the variable and.
So when you look at these installations at this point moving forward.
The biggest gain from a revenue and margin perspective, obviously going to occur in 2024.
So that's kind of a variable that we're looking at and I think we have been prudent we certainly haven't ever called it.
Got it that's helpful. Thanks, guys.
Thank you.
Thank you.
No additional questions at this time.
I will now hand, it back to Doug for closing remarks.
Thank you I want to thank everybody for your great questions in fact, I would just.
Pat.
We are the right questions and.
On behalf of our entire management team I want to thank you for your continued support and interest in quite the ortho now. This is a journey for sure and we look forward to sharing our journey with you.
That concludes today's conference call. Thank you you may now disconnect your lines.
Today's conference call. Thank you you may now disconnect your lines.
Okay.